Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-08-13

Clinical Trial Update: Selinexor Treatment of Refractory Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for selinexor in refractory multiple myeloma has completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Selinexor (selinexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2020-08-13